Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Dementia - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 166 | Code: MRS - 18394


Global Markets Directs, Dementia Pipeline Review, H1 2015, provides an overview of the Dementias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Dementia
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Dementia
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Dementia Overview 8
Therapeutics Development 9
Pipeline Products for Dementia - Overview 9
Pipeline Products for Dementia - Comparative Analysis 10
Dementia - Therapeutics under Development by Companies 11
Dementia - Therapeutics under Investigation by Universities/Institutes 14
Dementia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Dementia - Products under Development by Companies 19
Dementia - Products under Investigation by Universities/Institutes 22
Dementia - Companies Involved in Therapeutics Development 23
Actinogen Limited 23
Alector LLC 24
AlzProtect SAS 25
BioArctic Neuroscience AB 26
Biogen Idec Inc. 27
Biotie Therapies Corp. 28
Bristol-Myers Squibb Company 29
Chase Pharmaceuticals Corporation 30
Chronos Therapeutics Limited 31
Daewoong Pharmaceutical Co., Ltd. 32
Echo Pharmaceuticals B.V. 33
Eisai Co., Ltd. 34
FORUM Pharmaceuticals Inc. 35
Hyundai Pharmaceutical Co., Ltd. 36
Ildong Pharmaceutical Co., Ltd. 37
IMMD Inc. 38
ImStar Therapeutics Inc. 39
Integrative Research Laboratories Sweden AB 40
Intellect Neurosciences, Inc. 41
Intra-Cellular Therapies, Inc. 42
Neurimmune Holding AG 43
Oryzon Genomics S.A. 44
Otsuka Holdings Co., Ltd. 45
Pacific Northwest Biotechnology, LLC 46
ProteoTech, Inc. 47
SK Chemicals Co., Ltd. 48
Stelic Institute & Co. 49
Sumitomo Dainippon Pharma Co., Ltd. 50
Sylentis S.A. 51
TauRx Therapeutics Ltd. 52
Tautatis Incorporated 53
Varinel, Inc. 54
WhanIn Pharmaceutical Co., Ltd. 55
Dementia - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
Antisense Oligonucleotide to Inhibit microRNA for Neurology - Drug Profile 66
aripiprazole - Drug Profile 67
AVCRI-104P3 - Drug Profile 70
AZP-2006 - Drug Profile 71
brexpiprazole - Drug Profile 73
choline alfoscerate SR - Drug Profile 75
CPC-201 - Drug Profile 76
CPC-252 - Drug Profile 77
dehydroevodiamine hydrochloride - Drug Profile 78
dronabinol - Drug Profile 79
Drugs for Dementia - Drug Profile 81
Drugs to Agonize c-MET for Dementia - Drug Profile 82
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 83
DWJ-1365 - Drug Profile 84
E-2609 - Drug Profile 85
encenicline hydrochloride - Drug Profile 86
FRM-0334 - Drug Profile 89
GIBH-130 - Drug Profile 91
gugulipid - Drug Profile 92
IIPP-1 - Drug Profile 93
IMD-4482 - Drug Profile 94
IPN-007 - Drug Profile 95
IRL-752 - Drug Profile 96
ITI-007 - Drug Profile 97
KR-12 - Drug Profile 99
Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile 100
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 101
NAT - Drug Profile 102
NI-205 - Drug Profile 103
NI-308 - Drug Profile 104
NNC-269100 - Drug Profile 105
OG-635 - Drug Profile 106
PD-0805 - Drug Profile 107
PD-61W3 - Drug Profile 108
PD-61W3 Backup - Drug Profile 109
Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 110
PST-900 - Drug Profile 111
RDC-5 - Drug Profile 112
RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 114
SID-111 - Drug Profile 115
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 116
Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 117
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 118
Small Molecules to Inhibit LSD-1 And MAO-B for Neurodegenerative Diseases - Drug Profile 119
Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile 120
SYN-120 - Drug Profile 121
Synthetic Peptides for Neurological Disorders - Drug Profile 122
TAK-070 - Drug Profile 123
TauC-3 - Drug Profile 124
TPI-287 - Drug Profile 125
TRx-0237 - Drug Profile 127
TTT-3002 - Drug Profile 129
UE-2343 - Drug Profile 130
VAR-10100 - Drug Profile 131
WIB-1001C - Drug Profile 132
zonisamide - Drug Profile 133
Dementia - Recent Pipeline Updates 134
Dementia - Dormant Projects 150
Dementia - Discontinued Products 152
Dementia - Product Development Milestones 153
Featured News & Press Releases 153
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 162
Disclaimer 162

List of Tables

Number of Products under Development for Dementia, H1 2015 13
Number of Products under Development for Dementia - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Dementia - Pipeline by Actinogen Limited, H1 2015 27
Dementia - Pipeline by Alector LLC, H1 2015 28
Dementia - Pipeline by AlzProtect SAS, H1 2015 29
Dementia - Pipeline by BioArctic Neuroscience AB, H1 2015 30
Dementia - Pipeline by Biogen Idec Inc., H1 2015 31
Dementia - Pipeline by Biotie Therapies Corp., H1 2015 32
Dementia - Pipeline by Bristol-Myers Squibb Company, H1 2015 33
Dementia - Pipeline by Chase Pharmaceuticals Corporation, H1 2015 34
Dementia - Pipeline by Chronos Therapeutics Limited, H1 2015 35
Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 36
Dementia - Pipeline by Echo Pharmaceuticals B.V., H1 2015 37
Dementia - Pipeline by Eisai Co., Ltd., H1 2015 38
Dementia - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 39
Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2015 40
Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 41
Dementia - Pipeline by IMMD Inc., H1 2015 42
Dementia - Pipeline by ImStar Therapeutics Inc., H1 2015 43
Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2015 44
Dementia - Pipeline by Intellect Neurosciences, Inc., H1 2015 45
Dementia - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 46
Dementia - Pipeline by Neurimmune Holding AG, H1 2015 47
Dementia - Pipeline by Oryzon Genomics S.A., H1 2015 48
Dementia - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 49
Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H1 2015 50
Dementia - Pipeline by ProteoTech, Inc., H1 2015 51
Dementia - Pipeline by SK Chemicals Co., Ltd., H1 2015 52
Dementia - Pipeline by Stelic Institute & Co., H1 2015 53
Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 54
Dementia - Pipeline by Sylentis S.A., H1 2015 55
Dementia - Pipeline by TauRx Therapeutics Ltd., H1 2015 56
Dementia - Pipeline by Tautatis Incorporated, H1 2015 57
Dementia - Pipeline by Varinel, Inc., H1 2015 58
Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 59
Assessment by Monotherapy Products, H1 2015 60
Number of Products by Stage and Target, H1 2015 62
Number of Products by Stage and Mechanism of Action, H1 2015 65
Number of Products by Stage and Route of Administration, H1 2015 67
Number of Products by Stage and Molecule Type, H1 2015 69
Dementia Therapeutics - Recent Pipeline Updates, H1 2015 138
Dementia - Dormant Projects, H1 2015 154
Dementia - Discontinued Products, H1 2015 156

List of Figures

Number of Products under Development for Dementia, H1 2015 13
Number of Products under Development for Dementia - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 15
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Products, H1 2015 22
Assessment by Monotherapy Products, H1 2015 60
Number of Products by Top 10 Targets, H1 2015 61
Number of Products by Stage and Top 10 Targets, H1 2015 61
Number of Products by Top 10 Mechanism of Actions, H1 2015 64
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64
Number of Products by Top 10 Routes of Administration, H1 2015 66
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 67
Number of Products by Top 10 Molecule Types, H1 2015 68
Number of Products by Stage and Top 10 Molecule Types, H1 2015 69

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing